Seasonal influenza vaccine - paediatric adverse events

Seasonal influenza vaccine - paediatric adverse events
Melbourne, Australia - 23/04/2010

CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children. CSL is one of several suppliers of influenza vaccine in Australia.

CSL is urgently investigating these reports in association with the relevant regulatory bodies including the TGA and WA Health.

"As a further precautionary measure and in support of the Commonwealth Chief Medical Officer's decision advising GPs and immunisation providers to stop giving seasonal influenza vaccine to children under 5 years of age, CSL has taken the action to withhold further distribution of its paediatric influenza vaccine* nationally to reduce the risk of inadvertent administration in this age group" said Dr Darryl Maher, CSL Medical and Research Director.

The company takes the safety and quality of its products seriously and will provide more detailed information as soon as possible.

Media Contact:

Jo Lynch
Hinton & Associates
Phone: 61 3 9600 1979
Mobile: 61 411 208 101
Email: [email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.